Current chemotherapeutic strategies for rhabdomyosarcoma

References

• Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J. Clin. Oncol. 13, 2123–2139 (1995).
   PubMed Web of Science ®Google Scholar
• Ries LAG, Smith MA, Gurney JG et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1999. National Cancer Institute, MD, USA, NIH Publication No. 99-4649 (1999).
   Google Scholar
• Gurney JG, Young JL Jr, Roffers SD et al. Soft tissue sarcomas. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1999. National Cancer Institute, MD, USA, NIH Publication No. 99-4649 (1999).
   Google Scholar
• Newton WA, Gehan EA, Webber BL et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification – an Intergroup Rhabdomyosarcoma Study. Cancer 70, 1073–1085 (1995).
   Google Scholar
• Meyer WH, Spunt SL. Soft tissue sarcoma of childhood. Cancer Treat. Rev. 30, 269–280 (2004).
   PubMed Web of Science ®Google Scholar
• Ruymann FB, Grovas AC. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest. 18(3), 223–241 (2000).
   PubMed Web of Science ®Google Scholar
• Raney RB, Anderson JR, Barr FG et al. Rhabdomyosarcoma and undifferentiated sarcoma in first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J. Pediatr. Hematol. Oncol. 23(4), 215–220 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens M. Rhabdomyosarcoma. In: Evidence-based Paediatric Oncology. Pinkerton R, Philip T, Fervers B (Eds), BMJ Books, London, UK, 3–27 (2002).
   Google Scholar
• Maurer HM, Beltangady M, Gehan EA et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 61, 209–220 (1988).
   PubMed Web of Science ®Google Scholar
• Maurer HM, Gehan EA, Beltangady M et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 71, 1904–1922 (1993).
   PubMed Web of Science ®Google Scholar
• Crist WM, Garnsey L, Beltangady MS et al. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II. J. Clin. Oncol. 8, 443–452 (1990).
   PubMed Web of Science ®Google Scholar
• Crist WM, Gehan EA, Ragab AH et al. The third Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 13, 610–630 (1995).
   PubMed Web of Science ®Google Scholar
• Crist WM, Anderson JR, Meza JL et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol. 19, 3091–3102 (2001).
   PubMed Web of Science ®Google Scholar
• Flamant F, Rodary C, Rey A et al. Treatment of non-metastatic rhabdomyosarocmas in childhood and adolescence. Result of the second study of the International Society of Paediatric Oncology: MMT84. Eur. J. Cancer. 34(7), 1050–1062 (1998).
   PubMed Web of Science ®Google Scholar
• Stewart RJ, Martelli H, Oberlin O et al. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J. Clin. Oncol. 19, 793–798 (2003).
   Google Scholar
• Koscielniak E, Jurgens H, Winkler K et al. Treatment of soft tissue sarcoma in childhood and adolescence: a report of the German Co-operative Soft Tissue Sarcoma Study. Cancer 70(10), 2557–2567 (1992).
   PubMed Web of Science ®Google Scholar
• Koscielniak E, Harms D, Henze G et al. Results of treatment for soft tissue sarcoma in childhood and adolscence: a final report of the German Co-operative Soft Tissue Sarcoma Study CWS-86. J. Clin. Oncol. 17, 3706–3719 (1999).
   PubMed Web of Science ®Google Scholar
• Koscielniak E, Morgan M, Treuner J. Soft tissue sarcoma in children: prognosis and management. Paediatr. Drugs 4(1), 21–28 (2002).
   PubMedGoogle Scholar
• Carli M, Pastore G, Perilongo G et al. Tumour response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma. J. Clin. Oncol. 6, 654–658 (1988).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bisogno G, Casanova C et al. Paratesticular rhabdomyosarcoma: report from the Italian and German Co-operative Group. J. Clin. Oncol. 20, 449–455 (2002).
   PubMed Web of Science ®Google Scholar
• Carli M, Passone E, Perilongo G, Bisogno G. Ifosfamide in pediatric solid tumors. Oncology 65(Suppl 2), 99–104 (2003).
   PubMed Web of Science ®Google Scholar
• Harmer MH. TNM Classification of Pediatric Tumors. UICC International Union Against Cancer, Geneva, Switzerland, 23–28 (1982).
   Google Scholar
• Breneman JC, Lyden E, Pappo AS et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma – a report from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 21(1), 78–84 (2003).
   PubMed Web of Science ®Google Scholar
• Treuner J, Suder J, Keim M et al. The predictive value of initial cytostatic response in primary unresectable rhabdomyosarcoma. Acta Oncol. 28, 67–72 (1989).
   PubMed Web of Science ®Google Scholar
• Breitfeld PP, Anderson J, Kao S et al. Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience. Proc. Am. Soc. Clin. Oncol. 23 (2004) (Abstract 8513).
   Google Scholar
• Wharam MD, Meza J, Anderson J et al. Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the Third Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 22(10), 1902–1908 (2004).
   PubMed Web of Science ®Google Scholar
• Sung L, Anderson JR, Donaldson SS et al. Late events occurring five years or more after successful therapy in childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Eur. J. Cancer 40(12), 1878–1885 (2004).
   PubMed Web of Science ®Google Scholar
• Raney RB, Anderson JR, Kollath J et al. Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: report from the Intergroup Rhabdomyosarcoma Study (IRS)-III, 1984–1991. Med. Pediatr. Oncol. 34(6), 413–420 (2000).
   PubMedGoogle Scholar
• Paulino AC, Simon JH, Zhen W, Wen BC. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int. J. Radiat. Oncol. Phys. 48(5), 1489–1495 (2000).
   PubMed Web of Science ®Google Scholar
• Arndt C, Rodeberg D, Breitfeld PP et al. Does bladder preservation (as a surgical principle) lead to retain bladder function in bladder/prostate rhabdomyosarcoma? Report from the Intergroup Rhabdomyosarcoma Study IV. J. Urol. 17, 2396–2403 (2004).
   PubMed Web of Science ®Google Scholar
• Schuck A, Mattke AC, Schmidt B et al. Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary? J. Clin. Oncol. 22(1), 143–149 (2004).
   Web of Science ®Google Scholar
• Wolden SL, Anderson JR, Crist WM et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I to III. J. Clin. Oncol. 17, 3468–3475 (1999).
   PubMed Web of Science ®Google Scholar
• Viswanathan AK, Grier HE, Litman HJ et al. Outcome for childen with group III rhabdomyosarcoma treated with or without radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 58(4), 1208–1214 (2004).
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Anderson J et al. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment – results of an international workshop. J. Clin. Oncol. 19(1), 197–204 (2001).
   PubMed Web of Science ®Google Scholar
• Ruymann FB. The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore? Curr. Oncol. Rep. 5, 505–509 (2003).
   PubMedGoogle Scholar
• Pappo AS, Etcubanas E, Santana VM et al. A Phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer 71(6), 2119–2125 (1993).
   PubMed Web of Science ®Google Scholar
• Stevens M, Flamant F. Ifosfamide for children with solid tumours. Lancet 335, 1398–1400 (1990).
   Google Scholar
• Treuner J, Koscielniak E, Keim M. Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas. Cancer Chemother. Pharmacol. 24(Suppl.), S48–S50 (1989).
   Google Scholar
• Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children’s Cancer Study Group. Br. J. Cancer 82(10), 1636–1645 (2000).
   PubMed Web of Science ®Google Scholar
• Lee BS, Lee JH, Kang HG et al. Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr. Nephrol. 16(10), 796–799 (2001).
   PubMed Web of Science ®Google Scholar
• Ruymann FB, Vietti T, Gehan E et al. Cyclophoshamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. J. Pediatr. Hematol. Oncol. 17, 331–337 (1995).
   PubMed Web of Science ®Google Scholar
• Baker KS, Anderson JR, Link MP et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 18(12), 2427–2434 (2000).
   PubMed Web of Science ®Google Scholar
• Spunt SL, Smith LM, Ruymann FB et al. Cyclophoshamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Clin. Cancer Res. 10, 6072–6079 (2004).
   PubMed Web of Science ®Google Scholar
• Sandler E, Lyden E, Ruymann F et al. Efficacy of ifosfamide and doxorubicin given as a Phase II ‘window’ in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med. Pediatr. Oncol. 37, 442–448 (2001).
   PubMedGoogle Scholar
• Stevens MC, Rey A, Bouvet N et al. SIOP MMT 95: intensified (6 drug) versus standard (IVA) chemotherapy for high risk non-metastatic rhabdomyosarcoma (RMS). Proc. Am. Soc. Clin. Oncol. 23 (2004) (Abstract 8515).
   Google Scholar
• Treuner J, Brecht IB, Mattke AD et al. Interims report of the CWS-96-study: results of the treatment for soft tissue sarcomas in childhood. Med. Pediatr. Oncol. 41(4) (2003) (Abstract O-084).
   Google Scholar
• Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing’s sarcoma. J. Natl Cancer Inst. 83, 1460–1470 (1991).
   PubMed Web of Science ®Google Scholar
• Bisogno G, Ferrari A, Bergeron C et al. The IVADo regimen, a pilot study with ifosfamide, vincristine, actinomycin and doxorubicin in children with metastatic soft tissue sarcoma. A pilot study by the European pediatric Soft Tissue Sarcoma Study Group. Cancer (2005) (In Press).
   Google Scholar
• Breitfeld PP, Lyden E, Raney RB et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study. J. Pediatr. Hematol. Oncol. 23(4), 225–233 (2001).
   PubMed Web of Science ®Google Scholar
• Miser JS, Kinsella TJ, Triche TJ et al. Ifosfamide with Mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J. Clin. Oncol. 5(8), 1191–1198 (1987).
   PubMed Web of Science ®Google Scholar
• Horowitz ME, Etcubanas E, Christensen ML et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J. Clin. Oncol. 6(2), 308–314 (1988).
   PubMed Web of Science ®Google Scholar
• Smith MA, Anderson B. Phase II window studies: 10 years of experience and counting. J. Pediatr. Hematol. Oncol. 23(6), 334–337 (2001).
   PubMed Web of Science ®Google Scholar
• Blaney SM, Needle MN, Gillespie et al. Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children’s Cancer Group study. Clin. Cancer Res. 4, 357–360 (1998).
   PubMed Web of Science ®Google Scholar
• Nitschke R, Parkurst J, Sullivan J et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II study. J. Pediatr. Hematol. Oncol. 20, 315–318 (1998).
   PubMed Web of Science ®Google Scholar
• Pappo AS, Lyden E, Breneman J et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 19(1), 213–219 (2001).
   PubMed Web of Science ®Google Scholar
• Saylors RL, Stine KC, Sullivan J et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II study. J. Clin. Oncol. 19(15), 3463–3369 (2001).
   PubMed Web of Science ®Google Scholar
• Walterhouse DO, Lyden ER, Breitfeld PP et al. Efficacy of topotecan and cyclophosphamide given as a Phase II window in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J. Clin. Oncol. 22(8), 1–7 (2004).
   Google Scholar
• Cosetti M, Wexler LH, Calleja E et al. Irinotecan for pediatric solid tumors: the Memorial Sloan–Kettering experience. J. Pediatr. Hematol. Oncol. 24(2), 84–85 (2002).
   PubMed Web of Science ®Google Scholar
• Vassal G, Doz F, Frappaz D et al. A Phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J. Clin. Oncol. 21(20), 3844–3852 (2003).
   PubMed Web of Science ®Google Scholar
• Pappo AS, Lyden E, Breitfeld PP et al. Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma (RMS): a Phase II window trial from the Soft Tissue Sarcoma Committee (STS) of the Children's Oncology Group (COG). Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 1570).
   Google Scholar
• Carli M, Colombatti R, Oberlin O et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J. Clin. Oncol. 17(9), 2796–2802 (1999).
   PubMed Web of Science ®Google Scholar
• Koscielniak E, Klingebiel TH, Peters C et al. Do patients with metastatic and recurrent rhabdomysarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 19(3), 227–231 (1997).
   PubMed Web of Science ®Google Scholar
• Boulad F, Kernan NA, LaQuaglia MP et al. High-dose induction chemotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseus Ewing’s sarcoma and undifferentiated sarcoma. J. Clin. Oncol. 16, 1697–1706 (1998).
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Breitfeld PP, Hawkins D et al. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic and recurrent rhabdomyosarcoma. J. Pediatr. Hematol. Oncol. 23(5), 272–276 (2001).
   PubMed Web of Science ®Google Scholar
• Mackall CL, Helman LJ. High-dose chemotherapy for rhabdomyosarcoma: where do we go from here. J. Pediatr. Hematol. Oncol. 23(5), 266–267 (2001).
   PubMed Web of Science ®Google Scholar
• Meyers PA. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr. Opin. Oncol. 16, 120–125 (2004).
   PubMed Web of Science ®Google Scholar
• Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing’s sarcoma and soft tissue sarcomas in children. Eur. J. Cancer 36(1), 87–94 (2000).
   PubMed Web of Science ®Google Scholar
• Kamen BA, Rubin E, Aisner J, Glatstein E. High-time chemotherapy or high time for low dose. J. Clin. Oncol. 18, 2935–2937 (2000).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045–1047 (2000).
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuos low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann. Oncol. 13, 12–15 (2002).
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Koscielniak E, Beske F et al. High dose therapy versus oral maintenance: results of HD CWS 96 study for treatment of patients with metastasized soft tissue sarcoma. Med. Pediatr. Oncol. 41(4) (2003) (Abstract O-085).
   Google Scholar
• Bertolini F, Paul S, Mancuso P et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitors cells. Cancer Res. 63, 4342–4346 (2003).
   PubMed Web of Science ®Google Scholar
• Hayot C, Farinelle S, De Decker R et al. In vitro pharmacological characterizations of the anti-angiogenic and antitumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int. J. Oncol. 21, 417–425 (2002).
   PubMed Web of Science ®Google Scholar
• Kusnher BH, Kramer K, Cheung NKV. Oral etoposide for refractory and relapsed neuroblastoma. J. Clin. Oncol. 17, 3221–3225 (1999).
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield CE, Kraling BM et al. Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878–1886 (2000).
   PubMed Web of Science ®Google Scholar
• Casanova M, Ferrari A, Spreafico F et al. Vinorelbine in previously treated advanced childhood sarcomas. Evidence of activity in rhabdomyosarcoma. Cancer 94(12), 3263–3268 (2002).
   PubMed Web of Science ®Google Scholar
• Epelman S, Aguiar S, Melaragno R et al. High response rate of vinorelbine in children and adolescents with refractory or recurrent rhabdomyosarcomas or other sarcomas. Med. Pediatr. Oncol. 33(3) (1999) (Abstract P-147).
   Google Scholar
• Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: antivascular effects in a murine tumour. Eur. J. Cancer 29A, 1320–1324 (1993).
   PubMed Web of Science ®Google Scholar
• Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15–R24 (2000).
   PubMed Web of Science ®Google Scholar
• Nasti G, Errante D, Talamini R et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi’s sarcoma: results of a Phase II study. J. Clin. Oncol. 18, 1550–1557 (2000).
   PubMed Web of Science ®Google Scholar
• Casanova M, Ferrari A, Bisogno G et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas. Pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 101(7), 1664–1671 (2004).
   PubMed Web of Science ®Google Scholar
• Hawkins WG, Hoos A, Antonescu CR et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer 91, 794–803 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Dileo P, Casanova M et al. Rhabdomyosarcoma in adults: a retrospective analysis of 171 patients treated at a single institution. Cancer 98, 571–580 (2003).
   PubMed Web of Science ®Google Scholar
• Ablett S, Doz F, Morland B, Vassal G. European collaboration in trials of new agents for children with cancer. Eur. J. Cancer 40(12), 1886–1892 (2004).
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Adamson PC, Blaney S et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin. Cancer Res. 8, 3646–3657 (2002).
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Horton JK, Houghton JA. Drug sensitivity and resistance in the xenograft model. In: Rhabdomyosarcoma and Related Tumors in Children and Adolescents. Maurer HM, Ruymann FB, Pochedly C (Eds). CRC Press, FL, USA, 187–203 (1991).
   Google Scholar